Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.

Moritake H, Saito Y, Sawa D, Sameshima N, Yamada A, Kinoshita M, Kamimura S, Konomoto T, Nunoi H.

Cancer Med. 2019 Dec;8(18):7809-7821. doi: 10.1002/cam4.2647. Epub 2019 Nov 6.

2.

Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.

Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK.

Mol Cancer Ther. 2007 Apr;6(4):1357-67.

3.

Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.

Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Beer DG, Nagatsuka H, Tanaka N, Naomoto Y.

Clin Cancer Res. 2008 Jul 15;14(14):4631-9. doi: 10.1158/1078-0432.CCR-07-4755.

4.

Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.

Fukami S, Tomioka D, Murakami Y, Honda T, Hatakeyama S.

BMC Res Notes. 2019 Jun 18;12(1):347. doi: 10.1186/s13104-019-4389-7.

5.

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.

Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN.

Mol Carcinog. 2007 Jun;46(6):488-96.

PMID:
17219439
6.

Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.

Kurio N, Shimo T, Fukazawa T, Takaoka M, Okui T, Hassan NM, Honami T, Hatakeyama S, Ikeda M, Naomoto Y, Sasaki A.

Exp Cell Res. 2011 May 1;317(8):1134-46. doi: 10.1016/j.yexcr.2011.02.008. Epub 2011 Feb 19.

PMID:
21338601
7.

TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.

Golubovskaya VM, Virnig C, Cance WG.

Mol Carcinog. 2008 Mar;47(3):222-34.

PMID:
17849451
8.

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK.

Cancer Res. 2007 Nov 15;67(22):10976-83. Erratum in: Cancer Res. 2018 Jul 15;78(14):4100.

9.

TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.

Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Takaoka M, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.

Oncol Rep. 2008 Dec;20(6):1473-7.

PMID:
19020730
10.

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S.

PLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015.

11.

Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.

Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):536-43. doi: 10.1165/rcmb.2012-0277OC.

PMID:
23642017
12.

Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.

Kurio N, Shimo T, Fukazawa T, Okui T, Hassan NM, Honami T, Horikiri Y, Hatakeyama S, Takaoka M, Naomoto Y, Sasaki A.

Oral Oncol. 2012 Nov;48(11):1159-70. doi: 10.1016/j.oraloncology.2012.05.019. Epub 2012 Jul 4.

PMID:
22766511
13.

CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.

Sun H, Lin DC, Cao Q, Guo X, Marijon H, Zhao Z, Gery S, Xu L, Yang H, Pang B, Lee VK, Lim HJ, Doan N, Said JW, Chu P, Mayakonda A, Thomas T, Forscher C, Baloglu E, Shacham S, Rajalingam R, Koeffler HP.

Cancer Res. 2016 May 1;76(9):2687-97. doi: 10.1158/0008-5472.CAN-15-1572. Epub 2016 Mar 8.

14.

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.

Schultze A, Decker S, Otten J, Horst AK, Vohwinkel G, Schuch G, Bokemeyer C, Loges S, Fiedler W.

Invest New Drugs. 2010 Dec;28(6):825-33. doi: 10.1007/s10637-009-9326-5. Epub 2009 Sep 26.

PMID:
19784551
15.

High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.

Crompton BD, Carlton AL, Thorner AR, Christie AL, Du J, Calicchio ML, Rivera MN, Fleming MD, Kohl NE, Kung AL, Stegmaier K.

Cancer Res. 2013 May 1;73(9):2873-83. doi: 10.1158/0008-5472.CAN-12-1944. Epub 2013 Mar 27.

16.

Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, Eisenacher M, Schaefer KL, Poremba C, de Alava E.

Br J Cancer. 2009 Jul 7;101(1):80-90. doi: 10.1038/sj.bjc.6605104. Epub 2009 Jun 2.

17.

The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC.

Genes Cancer. 2012 Feb;3(2):102-16. doi: 10.1177/1947601912457024.

18.

Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.

Hao HF, Takaoka M, Bao XH, Wang ZG, Tomono Y, Sakurama K, Ohara T, Fukazawa T, Yamatsuji T, Fujiwara T, Naomoto Y.

Biochem Biophys Res Commun. 2012 Jul 13;423(4):744-9. doi: 10.1016/j.bbrc.2012.06.030. Epub 2012 Jun 13.

19.

Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.

Steinestel K, Trautmann M, Jansen EP, Dirksen U, Rehkämper J, Mikesch JH, Gerke JS, Orth MF, Sannino G, Arteaga MF, Rossig C, Wardelmann E, Grünewald TGP, Hartmann W.

Mol Oncol. 2019 Dec 6. doi: 10.1002/1878-0261.12610. [Epub ahead of print]

20.

3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.

Hehlgans S, Lange I, Eke I, Cordes N.

Radiother Oncol. 2009 Sep;92(3):371-8. doi: 10.1016/j.radonc.2009.08.001. Epub 2009 Sep 2.

PMID:
19729215

Supplemental Content

Support Center